# Dan T Vogl, Msce

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 77 papers | 6,241 citations | 126907 33 h-index | 82547 72 g-index |
| 78 all docs | 78 docs citations | 78 times ranked | 8251 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood, 2022, 139, 1289-1301. | 1.4 | 9 |
| 2 | A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2022, 97, . | 4.1 | 11 |
| 3 | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer Journal, 2022, 12, 27. | 6.2 | 19 |
| 4 | Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 2021, 181, 195. | 5.1 | 168 |
| 5 | Untangling immunotactoid glomerulopathy in the MGRS era. Kidney International, 2021, 99, 303-305. | 5.2 | 3 |
| 6 | Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. British Journal of Haematology, 2021, 193, 851-855. | 2.5 | 6 |
| 7 | A unique window of opportunity for practical reform of cancer clinical trials. Cancer, 2021, 127, 2855-2860. | 4.1 | 2 |
| 8 | Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking. Clinical Chemistry, 2021, 68, 230-239. | 3.2 | 11 |
| 9 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993. | 2.6 | 8 |
| 10 | Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. Journal of Clinical Oncology, 2021, , JCO2101754. | 1.6 | 0 |
| 11 | A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Molecular Cancer Therapeutics, 2020, 19, 1530-1538. | 4.1 | 81 |
| 12 | Selinexorâ€based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. British Journal of Haematology, 2020, 189, e126-e130. | 2.5 | 13 |
| 13 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440. | 7.2 | 54 |
| 14 | Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. Journal of Clinical Oncology, 2020, 38, 8506-8506. | 1.6 | 63 |
| 15 | Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738. | 27.0 | 460 |
| 16 | Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Advances, 2019, 3, 2487-2490. | 5.2 | 35 |
| 17 | Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of Clinical Oncology, 2019, 37, 589-597. | 1.6 | 184 |
| 18 | RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia, 2019, 33, 2006-2021. | 7.2 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 2019, 3, 2812-2815. | 5.2 | 133 |
| 20 | B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221. | 8.2 | 513 |
| 21 | Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. Blood, 2019, 134, 1872-1872. | 1.4 | 3 |
| 22 | Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood, 2019, 134, 1854-1854. | 1.4 | 5 |
| 23 | Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140. | 1.4 | 13 |
| 24 | Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863. | 1.4 | 13 |
| 25 | Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 335-345. | 0.4 | 88 |
| 26 | Carfilzomib-Associated Cardiovascular Adverse Events. JAMA Oncology, 2018, 4, e174519. | 7.1 | 196 |
| 27 | Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866. | 1.6 | 140 |
| 28 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, . | 5.0 | 140 |
| 29 | A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney International, 2018, 94, 199-205. | 5.2 | 90 |
| 30 | Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. Blood, 2018, 132, 1886-1886. | 1.4 | 19 |
| 31 | Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1872-1879. | 1.3 | 50 |
| 32 | Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica, 2017, 102, e261-e265. | 3.5 | 17 |
| 33 | Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899. | 2.0 | 34 |
| 34 | Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Letters, 2016, 371, 117-124. | 7.2 | 59 |
| 35 | Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 2119-2119. | 1.4 | 12 |
| 36 | Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491. | 1.4 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood, 2016, 128, 5702-5702. | 1.4 | 31 |
| 38 | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974. | 1.4 | 28 |
| 39 | Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematology,the, 2015, 2, e408-e416. | 4.6 | 158 |
| 40 | NY-ESO-1â€“specific TCRâ€“engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 2015, 21, 914-921. | 30.7 | 728 |
| 41 | Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 536-540. | 0.4 | 28 |
| 42 | Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1040-1047. | 27.0 | 511 |
| 43 | Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749. | 1.6 | 163 |
| 44 | Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 335-341. | 2.0 | 64 |
| 45 | Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clinical Cancer Research, 2014, 20, 1355-1365. | 7.0 | 116 |
| 46 | Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803. | 2.0 | 73 |
| 47 | Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). Blood, 2014, 124, 4764-4764. | 1.4 | 12 |
| 48 | Detection of the Malignant B Cell Clone in Multiple Myeloma Via High Throughput Sequencing Is Robust to Significant Levels of Somatic Hypermutation. Blood, 2014, 124, 3413-3413. | 1.4 | 0 |
| 49 | Salvage Second Hematopoietic Cell Transplantation inÂMyeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 760-766. | 2.0 | 98 |
| 50 | The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion, 2013, 53, 2314-2326. | 1.6 | 12 |
| 51 | Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. Molecular Cancer Therapeutics, 2012, 11, 2321-2330. | 4.1 | 12 |
| 52 | Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood, 2011, 117, 788-797. | 1.4 | 148 |
| 53 | Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2011, 17, 1765-1774. | 2.0 | 53 |
| 54 | The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 111, 326-332. | 1.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology, The, 2011, 12, 1195-1203. | 10.7 | 263 |
| 56 | Transfer of influenza vaccineâ€“primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood, 2011, 117, 63-71. | 1.4 | 41 |
| 57 | Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood, 2011, 118, 1979-1988. | 1.4 | 77 |
| 58 | Scleromyxedema and dermatoâ€“neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. American Journal of Hematology, 2011, 86, 893-896. | 4.1 | 29 |
| 59 | Crystalâ€storing histiocytosis in plasma cell myeloma. American Journal of Hematology, 2010, 85, 444-445. | 4.1 | 8 |
| 60 | Rapid Immune Recovery and Graft-versus-Host Diseaseâ€“like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells. Clinical Cancer Research, 2009, 15, 4499-4507. | 7.0 | 91 |
| 61 | A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research, 2009, 15, 6732-6739. | 7.0 | 97 |
| 62 | Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2009, 147, 531-534. | 2.5 | 27 |
| 63 | Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Medical Oncology, 2008, 25, 299-302. | 2.5 | 8 |
| 64 | Hypertriglyceridemia presenting as â€œpink bloodâ€•and elevated hemoglobin level. American Journal of Hematology, 2008, 83, 253-253. | 4.1 | 0 |
| 65 | Successful use of the antiâ€CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2008, 83, 747-749. | 4.1 | 63 |
| 66 | A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research, 2008, 14, 5619-5625. | 7.0 | 32 |
| 67 | The Rationale for Combined Proteasome and Autophagy Inhibition in Multiple Myeloma Established Using Novel Translational Platforms. Blood, 2008, 112, 2755-2755. | 1.4 | 3 |
| 68 | A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma. Blood, 2008, 112, 5188-5188. | 1.4 | 2 |
| 69 | Medical management update: Multiple myeloma. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2007, 103, 599-609. | 1.4 | 36 |
| 70 | Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. Leukemia and Lymphoma, 2007, 48, 885-891. | 1.3 | 40 |
| 71 | Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. American Journal of Hematology, 2007, 82, 1071-1075. | 4.1 | 15 |
| 72 | Successful Treatment of T-cell Post-Transplant Lymphoproliferative Disorder with the Retinoid Analog Bexarotene. American Journal of Transplantation, 2005, 5, 2070-2073. | 4.7 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leukemia and Lymphoma, 2005, 46, 1313-1320. | 1.3 | 20 |
| 74 | Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases.. Blood, 2005, 106, 1507-1507. | 1.4 | 0 |
| 75 | Symptom Prevalence, Characteristics, and Distress in AIDS Outpatients. Journal of Pain and Symptom Management, 1999, 18, 253-262. | 1.2 | 183 |
| 76 | Post-traumatic stress disorder in cancer: a review. , 1999, 8, 521-537. | | 210 |
| 77 | Postâ€traumatic stress disorder in cancer: a review. Psycho-Oncology, 1999, 8, 521-537. | 2.3 | 5 |